MedPath

011504 DAPSONE 8.5% / NIACINAMIDE 4%

011504 DAPSONE 8.5% / NIACINAMIDE 4%

Approved
Approval ID

a97aeb21-4efc-3d91-e053-2995a90a2298

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 2, 2020

Manufacturers
FDA

Sincerus Florida, LLC

DUNS: 080105003

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

011504 DAPSONE 8.5% / NIACINAMIDE 4%

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code72934-1212
Product Classification
G
Generic Name
011504 DAPSONE 8.5% / NIACINAMIDE 4%
Product Specifications
Route of AdministrationTOPICAL
Effective DateJuly 2, 2020
FDA Product Classification

INGREDIENTS (2)

NIACINAMIDEActive
Quantity: 4 g in 100 g
Code: 25X51I8RD4
Classification: ACTIB
DAPSONEActive
Quantity: 8.5 g in 100 g
Code: 8W5C518302
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

011504 DAPSONE 8.5% / NIACINAMIDE 4% - FDA Drug Approval Details